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The Health Research Board (HRB) is the lead agency in Ireland supporting and funding health 
research. The organisation also maintains health information systems and conducts research linked to 
national health priorities. Our aim is to improve people’s health, build health research capacity, underpin 
developments in service delivery and make a significant contribution to Ireland’s knowledge economy.
Core areas of work
Funding health research
Funding and supporting innovative health research to improve health, prevent illness and combat disease is 
central to the HRB’s mission. The HRB currently has a portfolio of research investments worth €100 million 
in hospitals, universities, institutions and charities on the island of Ireland.
Hosting information systems
The HRB is responsible for managing five national information systems. These systems ensure that valid and 
reliable data are available for analysis, dissemination and service planning. The data from these systems are 
used to inform policy and practice in the areas of disability, drug and alcohol use and mental health. 
Conducting research
Our main areas of in-house research include children’s health, mental health and alcohol and drug use.  
The research that we have undertaken provides evidence for changes in the approach to service delivery.  
It also highlights the requirement for additional resources to support people who need services for drug  
and alcohol misuse, mental health conditions and intellectual, physical and sensory disabilities.
Mission and objectives 2001–2006
To improve health through research and information
In 2006 the Health Research Board continued to deliver successful results in line with the objectives of the 
Corporate Strategy 2002–2006:
To encourage the creation and application of knowledge for health and social gain, the growth of 
intellectual property and evidence relevant to health and social gain and the emergence of a knowledge-
based health system, economy and society.
To be the lead national organisation in relation to support for scientific research for health and social 
gain, including basic and translational research, health services research, population health and practice-
based research.
To promote the growth of a value-added research and development capability in the health system, in 
partnership with other relevant health organisations.
To impact on health and social policy and services through high-quality research and information.
To be the main advocate for the development of research for health and social gain.
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“ In 2006 there were major developments 
  that will shape the future of health research  
 in Ireland.” 
Major developments that will shape the 
future of health research took place in 
Ireland in 2006. The Government’s Strategy 
for Science, Technology and Innovation 
identified national priorities for health 
research.  Expanding on those priorities, the 
report of the Advisory Council for Science, 
Technology and Innovation (ACSTI) set out 
an agenda for achieving a step change in 
the level and quality of health research in 
Ireland. The Health Research Board (HRB) 
developed its Corporate Strategy 2007–2011 
to reflect the strategy’s priorities for health 
research and to embrace the opportunities 
and challenges inherent in the step change 
recommended by the ACSTI.
The ACSTI report, Towards better health: 
Achieving a step change in health research in 
Ireland, outlines an integrated, competitive 
health research agenda. It recognises the 
potential that research has to improve 
people’s health, to create a better health 
system and to help embed the healthcare 
industry here in Ireland. The HRB will work 
with other agencies to help realise the vision 
outlined in the report, which is ‘to drive 
a step change in the level and quality of 
health research, to enhance the health and 
wellness of the population and to build an 
international reputation for Ireland in health 
research through excellence and innovation’.
The HRB has taken steps to put in 
place a strong infrastructure to support 
developments in health research.  
Key achievements in 2006 included:
Partnering the Wellcome Trust in the 
creation of a clinical research facility in 
Ireland that will support experimental 
medicine and ultimately improve the 
health of patients. The investment of 
€20 million in this HRB/Wellcome 
Trust Clinical Research Facility and its 
associated network in Dublin is a mark of 
the excellent international reputation of 
Irish clinical research. The research team, 
led by Professor Dermot Kelleher on 
behalf of the Dublin Molecular Medicine 
Centre, must be congratulated for their 
highly competitive proposal, which was 
described by the international scientific 
advisory committee as ‘outstanding’. 
Engaging with the Health Service 
Executive to secure funding for the 
building costs of clinical research 
facilities in Galway and Cork. The HRB 
will fund the operating and research costs 
of these facilities for a five-year period.
Co-funding, with the Health Service 
Executive, the set-up costs of the 
Irish Clinical Research Infrastructure 
Network (ICRIN). ICRIN will provide a 
framework for co-operation between the 
proposed clinical research facilities and 
other groups engaged in clinical research 
so that maximum value can be added 
to the Wellcome/HRB/HSE investment 
for the benefit of Irish patients and the 
profile of Irish clinical research.
Securing an additional €10m for  
health research in 2007–8 under the 







Ensuring that health research was 
featured in the Strategy for Science 
Technology and Innovation and in the 
National Development Plan. 
Taking further action to increase the 
number and quality of post-doctorate 
researchers in Ireland by launching a 
second call to institutions to host a 
HRB PhD Scholar programme. The 
call focused on the areas of clinical 
and biomedical science, health services 
research and epidemiology and public 
health. This will help support the 
government objective to substantially 
increase the number of researchers in 
Ireland by 2013. 
Agreeing a memorandum of 
understanding with the Department 
of Foreign Affairs, whereby the HRB 
agreed to work with Irish Aid in inviting 
applications for funding for research on 
global health issues related to the policy 
areas of Ireland’s development assistance 
programme. Over €2 million was 
awarded to successful projects.
Co-funding the first joint call for 
research projects that are closely inked to 
improved patient care with the Medical 
Research Charities Group.
Appointing the third HRB clinician 
scientist, Dr Peter Kelly, Mater Hospital, 
an expert in the care of patients who 
have suffered a stroke. 
The HRB’s influence is also extending into 
Europe. This year, the Chief Executive 
successfully chaired the Working Group 
on Biology and Medical Sciences of the 
European Strategy Forum for Research 
Infrastructures in preparing a European 
Roadmap for Research Infrastructures. 
The Roadmap, published in October 
2006, presents 35 large-scale research 
infrastructures across a range of disciplines 
which are required by European scientists 
to do cutting edge research over the next 
10–15 years. This is a big step forward 
for European science. It is the first time 
that Europe has identified and prioritised 






European science a competitive edge over 
Asia and the US. It is also good to see that 
the infrastructures identified for biology and 
medical sciences at European level fit neatly 
with infrastructure priorities that the HRB 
has already identified for Ireland. 
I would like to pay tribute to Dr Barrington 
for the key role she has played in raising 
awareness of the importance of health 
research over the past nine years. This is 
evident through the major increase in HRB 
funding that is available. She has been 
an ambassador for health research, both 
nationally and internationally, in face of 
major changes. I wish her well for whatever 
challenge lies ahead.
I would also like to thank my fellow 
board members and HRB staff for their 
support and commitment. I appreciate their 
advice and direction with regard to the 
HRB Corporate Strategy 2007 – 2011 in 
particular.
The climate for health research in Ireland 
has never been better. We now need to work 
even more closely with the Department of 
Health and Children and the Health Service 
Executive to make sure that the support and 
resources are available to build capacity, 
support career paths in research and develop 
research programmes that will benefit 




The HRB has earned widespread regard 
from key stakeholders for delivering on its 
mission and for the quality of its research 
evaluation and funding processes. This is 
confirmed by the report of the international 
review panel (see appendix one) which 
examined how the HRB was performing and 
provided advice on its future development. 
The report of the panel, presented in January 
2006, confirmed that:
The HRB is addressing challenges 
effectively and appropriately, despite 
resource constraints and the limited size 
of the organisation. 
Other research funding organisations 
are unanimous in acknowledging the 
importance of the role of the HRB in 
research funding.
The HRB is playing an important role in 
North/South co-operation. 
The review panel reported that the 
organisation has reached a very promising 
stage in its strategic development, but 
that the environment in which the HRB 
is working has changed radically in the 
past 10 years. The panel suggested that the 
HRB seize the opportunities created by the 
changes in the research environment and 
recommended some internal reorganisation: 
a greater strategic focus by the Board 
the reorganisation of management 
structures around research funding, 
health information and in-house research 






the development of existing HRB 
processes to reflect change.
The Board adopted the panel’s report and 
the HRB developed a quality improvement 
plan to put the panel’s recommendations 
into effect. By the end of the year, the 
HRB had been restructured into three 
Directorates based on our core functions, 
and key processes were realigned, with the 
objective of increasing the strategic capacity 
of management and the decision-making 
capacity within the organisation. 
A major achievement during the year was 
the development of a new corporate strategy 
to provide direction for the period 2007–
2011. The Board led in preparing the new 
strategy, taking into consideration the rapid 
changes in the external environment and 
the recommendations of the organisational 
review panel. 
The challenge in developing our strategy 
was to balance our roles in addressing the 
research and information needs of the health 
service, in supporting the universities to 
conduct world-class research and in ensuring 
that health research contributes to the 
knowledge economy and society in Ireland.  
We consulted with key stakeholders on the 
draft strategy. We explored and discussed 
many of the issues to be addressed in the 
strategy at our first national conference 
in Dublin Castle in June. The publication 
of the Government’s Strategy for Science 
Technology and Innovation also provided 
an excellent backdrop to the HRB’s work in 
defining its vision, mission, objectives and 
■
Chief Executive’s Report
“ The HRB has earned widespread regard   
from key stakeholders for delivering on its   
mission and for the quality of its research   
evaluation and funding processes.”
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high-level actions. The Corporate Strategy 
2007–2011 was adopted by the Board in 
November 2006 and is available on the HRB 
website at www.hrb.ie. The management 
team has developed an implementation plan 
that will help ensure that we deliver on the 
ambitious targets of the strategy over the 
next five years.
Our Chairman has mentioned some of the 
HRB’s key achievements in 2006.  Other 
important initiatives taken by the HRB in 
2006 include:
Commissioning studies, in association 
with the HSE, to measure the impact of 
demographic change on demand for and 
delivery of health services and to develop 
a resource allocation model for the health 
service. 
Commissioning a study on the prevalence 
of chlamydia in the Irish population 
on behalf of the Health Protection 
Surveillance Centre of the HSE.
Investing €40 million to support 
health research. This will be spent on 
developing people’s skills, providing 
infrastructure and supporting new 
research projects related to health.
Establishing in-house research 
programmes in health inequalities and 
problem alcohol use.
Introducing a new seminar, ‘Let’s 
talk health research’, to help the next 
generation of health researchers develop 
the skills to communicate their research 
more effectively.
Publishing a wide variety of research 
publications in the areas of mental 








In September, I informed the Board that I 
would step down as Chief Executive at the 
end of May 2007. I would like to thank the 
members of the Board and, in particular, the 
Chair, Professor Fitzgerald, for the support, 
encouragement and leadership they have 
provided for the organisation during the 
past five years. 
I commend the staff of the HRB, and 
especially my colleagues on the management 
team, for their extraordinary commitment 
to our mission to improve people’s health 
and develop our health services. It is this 
commitment, underpinned by hard work, 
which has brought the organisation to its 
present state of development. I wish the 
Health Research Board every success in the 
challenges and opportunities that present for 
health research in the future.
Ruth Barrington PhD
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The year at a glance 
This diagram shows ‘at a glance’ some of our core deliverables in 2006. It also highlights some of the 

















presented to the Board
Work commences with 
MRCG on grant application 
processes to manage the €2 
million new funding.
Annual Grave’s Lecture




Alcohol research becomes 
part of HRB brief
What’s health research done 
for you? Latest edition of the 
Picture of health published.
‘Let’s talk health
research’ seminar
New research into drugs
and crime published
New Global Health awards
announced with Irish Aid
First HRB national conference: 
Today’s health Research is 
tomorrow’s health care
Launch of all major grant and
fellowship calls
Report reviews level of infectious 
diseases among drug users
Family Support Study for living with 
enduring mental illness launched
Mental Health Census highlights
increase in community care
New report looks at Primary care
R&D capacity in Ireland
Major external events
          Government Strategy for STI launched              HIQA CEO appointed              Step change for health research report, ACSTI NovAugJune
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Key activities and achievements  
in 2006
Research strategy and funding
The HRB currently supports a research 
portfolio of €100 million for projects 
throughout the island of Ireland. We 
support a broad range of health research 
that we hope will improve links between 
the laboratory and the delivery of patient 
care – we want to bring research and 
development to life. Our funding is therefore 
focused on building up people’s research 
capability, providing relevant equipment 
and infrastructure and supporting research 
programmes in a wide variety of areas. 
During 2006, new awards in health research 
amounted to more than €40 million. We 
received a total of 1,149 applications for 
funding across grant and training schemes 
and we made a total of 535 awards.






Career support schemes and capacity building
Summer Student Scholarships 135 70
NCI Summer Curriculum (Cancer Consortium) 35 25
Post-Doctoral Research Fellowships 50 8
Clinical Research Training Fellowships 37 7
Health Services Research Fellowships 20 4
Clinical Fellowships in Nursing and Midwifery 16 4
Research Fellowships for the Therapy Professions 21 5
Cancer Prevention Fellowship (Cancer Consortium) 1 1
Cochrane Fellowships 5 3
Clinician Scientist Awards 4 1
Research grants
Project Grants 339 75
Building Partnerships for a Healthier Society Awards 17 6
HRB/ Medical Research Charities Group Co Funding 42 33
Translational Research Awards 22 4
Junior Clinician Scientist for Nursing and Midwifery 3 2
Global Health Research Awards 16 6
Career support schemes and capacity building
Infrastructure grants
Additional Capital Awards 74 74
Autism Genome Project 1 1
Irish Clinical Research Infrastructure Network 1 1
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Training and workshops 
HRB Scientific Writing Workshops 133 80
Half-day Introduction to The Cochrane Collaboration 53 53
Cochrane two-day course on systematic reviews 121 68
Nursing Clinical Trials Training (Cancer Consortium) 3 2
Commissioned projects
Research into the optimal setting for chlamydia screening in Ireland 1
Nursing and Midwifery Research Priorities studies 1
Infrastructure
Infrastructural investments in 2006 focused 
on the development of clinical research 
facilities. We also saw the introduction of 
state-of-the-art imaging equipment based on 
awards made during 2005.
In June the HRB/Wellcome Trust Clinical 
Research Facility (CRF) was announced. 
The aim of the facility is to provide the 
infrastructure – the physical space, facilities 
and the experts – needed to support 
patient-focused research studies. The joint 
investment by the Wellcome Trust and the 
HRB will be of the order of €20 million 
over the next five years.
This investment is a major boost for clinical 
research and patient care in Ireland and 
it will provide a world-class environment 
for patient-focused research with real 
benefits for patients. The CRF will provide 
a means for clinicians, the healthcare 
industry and other key partners to test 
innovative therapies, technologies and 
products and increase the speed at which 
scientific discoveries and innovations can be 
translated into improved patient care. 
Based in St James’s Hospital, the CRF will 
provide patients with access to the latest 
advances in diagnosis and treatment of 
conditions such as cancer, neuro-psychiatric 
disorders and infectious diseases. It will also 
connect with new and emerging facilities at 
other Dublin teaching hospitals by means of 
a city-wide clinical research network which 
is being established to help ensure that the 
greatest number of patients will benefit from 
clinical research in the most cost-effective 
manner.
The facility is expected to open in March 
2009. The successful proposal came from 
three Dublin medical schools at Trinity 
College, University College Dublin and 
the Royal College of Surgeons in Ireland 
and their affiliated teaching hospitals. The 
proposal was led by Professor Dermot 
Kelleher, based at Trinity College/St James’s 
Hospital, and was co-ordinated through the 
Dublin Molecular Medicine Centre.
External view of the clinical research facility  
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Imaging equipment 
The HRB awarded €4 million in 2005 to a 
new all-Ireland clinical research consortium, 
Perinatal Ireland, to provide essential 
ultrasound equipment and support staff to 
carry out a research programme which aims 
to reduce sickness and mortality of babies 
before and soon after birth. Perinatal Ireland 
is a multi-centre research collaboration 
between leading consultant obstetricians in 
eight of the principal maternity hospitals 
across the island of Ireland and led by the 
Royal College of Surgeons in Ireland (RCSI).
Work was well under way during 2006 to 
introduce the equipment to all hospital sites. 
A primary objective of Perinatal Ireland will 
be to use the latest ultrasound technologies 
and equipment to enhance observation 
and improve the detection of abnormalities 
while the baby is in the womb. The HRB 
is funding the ultrasound equipment 
and computer hardware, image analysis 
equipment and dedicated research personnel. 
Careers
Encouraging the best people into research 
is competitive and in Ireland there is a real 
need for people to be able to see a clear 
career path. Two HRB initiatives that will 
help to achieve this are the extension of 
the Clinician Scientist Awards and the PhD 
Scholar schemes.
The HRB appointed a third Clinician 
Scientist during 2006. Dr Peter Kelly is a 
medically qualified researcher who will be 
released from his service commitments to 
dedicate time to patient-centred research. 
Dr Kelly will examine a population-based 
prospective cohort to help predict recurrent 
stroke after a transient ischaematic attack or 
first incidence of stroke.
We also announced new funding for the 
appointment of up to four more Clinician 
Scientist positions in 2007. This will more 
than double the existing complement of 
Clinician Scientists in Ireland, which is a real 
step forward.
A new call was issued to institutions 
interested in hosting PhD scholar 
programmes in clinical and biomedical 
science, health services research or 
epidemiology and public health. Up to 
€5 million is available for each successful 
application. 
The HRB was one of the first Irish research 
agencies to respond to concerns about 
the quality of PhD training in Ireland by 
launching a pilot PhD scholars training 
scheme in 2004. These pilot sites are now 
considered to be a strong model for the 
development of PhD training, so it is a 
strategic move to extend the scheme and 
contribute to the national goal of increasing 
the number and quality of PhD researchers 
in Ireland.
Projects 
The extent and variety of research supported 
by the HRB is extensive, so we cannot 
capture every success story here. The 
examples below illustrate some of the results 
that emerged from our funded research 
projects during 2006, along with some new 
projects funded in 2006 which have great 
potential to yield important results. 
Summary of funding outcomes in 2006 
During 2006, 58 of the projects that we fund 
were completed. We have been evaluating 
the impact of this research by measuring the 
number of publications that were produced, 
the number of conferences people were 
invited to speak at and how many lead to 
further funding. This is illustrated in more 
detail in the table overleaf.
Grant holders were also successful with 
regard to collaboration, ensuring their 
findings influenced policy, using novel 
research techniques. Sixteen of the 58 grant 
holders received national or international 
awards for their work.
■
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Results of some of our funded 
research published in 2006
Motor neurone disease breakthrough
Dr Orla Hardiman, consultant neurologist 
at Beaumont Hospital and senior lecturer at 
the Royal College of Surgeons in Ireland, led 
an international team that recently identified 
a gene that causes motor neurone disease 
(MND) in some people. The breakthrough 
is shedding light on the root causes of the 
crippling condition and could one day 
deliver a new treatment. The RCSI has filed 
a patent to search for a potential drug.
Prescribing indicators for GPs
Developing quality prescribing indicators 
that reflect the everyday use of medicine 
and are acceptable and applicable in the 
Irish healthcare system was the focus of 
research completed by Professor John Feely 
of the Department of Pharmacology and 
Therapeutics in Trinity College Dublin. 
Professor Feely’s study revealed that:
Quality prescribing indicators are feasible 
and generally acceptable to GPs.
The HSE Primary Care Reimbursement 
■
■
Services database could provide feedback 
to GPs on their prescribing practices as a 
routine service and further improve the 
general quality of prescribing nationally.
There is evidence of social inequalities 
with regard to the standards of 
prescribing in vulnerable populations. 
It is possible to identify areas where a 
therapy has been omitted on a national 
basis and by combining survey and 
practice data it is possible to identify  
a ‘knowledge deficit’.   
The research shows that it is possible to 
enhance knowledge in this area by way 
of directed bulletins. Professor Feely has 
given a preliminary presentation of his 
research to the HSE and has encouraged 
the development of an ongoing forum of 
education about GP prescribing in the 
community.
MRSA discovery
There was considerable excitement 
during the year when scientists from NUI 
Maynooth discovered a new group of 
antibiotics that could be effective against 







Peer reviewed Mean per project Other Mean
104 1.7 64 1.1
Presentations – Oral
National International Total Mean
55 74 129 2.2
Presentations – Poster 72 102 174 3
Total abstracts published in 
conference proceedings 137




Applied Plan to Apply
4 3
Table 1   Outputs from projects completed in 2006
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therefore have enormous potential for 
the treatment of MRSA.  In the course of 
Professor Bernard Mahon’s HRB-supported 
study of how asthma develops, his team 
noticed a naturally occurring, mild antibiotic 
in the lungs.  The team used a number 
of advanced techniques to develop the 
compound until it was much stronger and 
able to disrupt the cell walls of bacteria 
such as MRSA.  The novel compound is 
less likely to provoke adverse reactions 
than existing treatments as it is based on a 
naturally occurring human substance.  The 
team has engaged with Enterprise Ireland to 
help scale up production of the antibiotic for 
potential application.
HRB funding provides critical stepping stone 
A HRB-funded project, valued at 
approximately €200,000, has led to a €3.3 
million award under the Nanoscience, 
Nanotechnology and New Materials 
programme in the European Union’s Sixth 
Framework Programme (FP6). The HRB 
project grant, originally awarded in 2002, 
involved the characterisation of biomaterials 
using advanced methods of transcriptomics 
and proteomics. The initial project was led 
by Professor Kenneth Dawson and Dr Iseult 
Lynch of the Department of Chemistry in 
UCD and Professor William Gallagher of 
the Conway Institute, UCD. Up until 2002, 
little work had been done on the detailed 
intra- and inter-cellular process triggered by 
contact of cells with foreign material. 
Professor Dawson believes that the HRB 
funding of this project contributed to its 
success in achieving the FP6 award as it 
allowed the researchers to develop and apply 
novel ‘omics’ methods to the question of 
protein-material interactions to a standard 
that showed the effects of the materials on 
biological cells. This research is important 
as human risk on exposure to nanoparticles 
is becoming a scientific as well as a global, 
political and societal concern. An Irish 
Consortium has been built up involving 
researchers in UCD, TCD, UCC, UL and 
NUI Maynooth to deliver the FP6 project.
Key developments in cystic fibrosis research
Researchers at the Royal College of 
Surgeons in Ireland and at Beaumont 
Hospital have identified two possible 
mechanisms which could treat the root cause 
and not just the symptoms of cystic fibrosis. 
Clinical trials have already started, and it 
is hoped that the first results will become 
available in 2007. With one in 19 Irish 
adults carrying the gene for cystic fibrosis, 
it is the most common life-threatening 
inherited disease in Ireland. When each 
parent carries the gene, there is a one in 
four chance that their child will have cystic 
fibrosis.
New research projects funded 
in 2006
The HRB committed more than €16.6 
million for completely new research projects 
during 2006. More than 200 research 
projects or initiatives started during the 
year. They span a wide range of subjects 
including:  
A random controlled trial on the 
evaluation of an alcohol intervention 
programme in a sports setting (Trinity 
College Dublin)
An all-Ireland pancreatic case-control 
study: establishing a data and specimen 
bank for research into diagnosis, 
aetiology and survival from cancer of the 
pancreas (National Cancer Registry)
A metabolic profiling of epilepsy  
(University College Dublin)
Recruitment, adaptation and retention of 
foreign nurses in Ireland (Royal College 
of Surgeons in Ireland)
Providing meaningful care: learning from 
the experiences of suicidal men to inform 
mental health care services (Dublin City 
University)











Communicating the impact of 
health research
Communicating the value and impact of 
health research is essential. If patients and 
stakeholders do not make the link between 
research activity and improvements in health 
care delivery and in patient outcomes, 
they will not appreciate the importance of 
continued investment in R&D. Each year 
the HRB continues to develop initiatives 
to encourage the research community 
to explain clearly the outcomes of their 
research.
A Picture of Health – A selection of Irish 
health research 2006. The aim of this 
publication is to help us share with the 
wider public the discoveries being made by 
HRB-funded researchers. It captures the 
latest research outcomes and reports them 
as feature articles. In 2006 we introduced a 
companion series of short booklets based on 
these features. These booklets were designed 
for people with particular conditions, and 
were circulated through clinics, surgeries and 
hospitals nationwide. We hope that people 
who read these booklets will have a better 
understanding of the link between health 
research and the delivery of patient care.
Let’s Talk Health Research Seminar 
–The HRB introduced this new event to 
develop the communication skills of the 
next generation of HRB researchers. The 
event was well received by more than 120 
delegates, who took away valuable messages 
about the importance of communicating 
their research, how to present their research 
in a more understandable way to a lay 
audience and how to engage media interest 
in their work. 
During the day, a group of finalists selected 
through a competitive process had the 
opportunity to present their work and to 
contend for the Watts Medal or one of the 
new HRB research communication prizes.  
The winners were: 
 
The Watts Medal - Daniel Yu, who  
carried out his eight-week project under 
the supervision of Dr Anne Hopkins at the 
Conway Institute, Dublin.  The title of his 
presentation was ‘Migratory characteristics 
of cancer cells from in situ versus invasive 
tumours’.
The HRB Research Communication Awards
Nollaig Healy, UCC, Mystique: a new 
mediator of metastasis and invasion in cancer
Frank Doyle, RCSI, Impact of briefly-
assessed depression on mortality and heart 
disease prevention behaviours after heart 
attack or angina
A Picture of HeAltH







easing the burden of diabetes
the price of better health
Brainwaves




The HRB makes a major contribution to 
improving health and developing the ef-
fectiveness of the health services through our 
in-house research and information activities. 
The information systems we manage require 
ongoing data collection and analysis to pro-
vide the most up-to-date evidence for service 
planning and decision making in relation 
to drug use, mental health and disability. 
The real benefit of these databases is that 
they can draw attention to the areas where 
additional services are needed most. This 
is essential information that enables health 
service managers and policy makers to make 
more effective decisions about services for 
people who need them.
In addition to collecting the data, we publish 
reports that analyse the trends from the 
information collected.  We are also engaged 
in a variety of research projects in relation 
to child health, mental health and drug use. 
Some of the main projects of the year are 
highlighted below.  
Mental Health Information 
Systems
The HRB made a strategic move in 2006 
to merge two existing mental health 
databases. The existing system, the National 
Psychiatric In-patient Reporting System, 
which records admissions and discharges to 
inpatient psychiatric services nationally, will 
be brought together with the community 
mental health system, COMCAR, which 
is being developed to record activity in 
community care facilities. This merger 
reflects the change in mental health care in 
Ireland from inpatient to community-based 
services. Plans to roll out the new joint 
system as a pilot project in the Donegal 
region have been agreed with the HSE.
HRB psychiatric inpatient  
Census 2006
The HRB conducted a census of Irish 
psychiatric units and hospitals on 31 March 
2006. The census found that the number 
of people resident had fallen by 83% in the 
past 43 years, from 19,801 in 1963 to just 
3,389 in 2006. The continuing decline in 
numbers of long-stay patients is a result of 
the further development of community care, 
discharges and long term patients passing 
away. Given these changes, the authors 
predict that existing public psychiatric 
hospitals should be in a position to close  
by 2010.  The key findings of the census  
can be found on the HRB website at  
www.hrb.ie/publications.
Family Support Study 
The HRB conducted a Family Support 
Study which reveals the experiences, needs 
and support requirements of people who 
care for a family member with enduring 
mental illness in Ireland. The exploratory 
study found that different services are 
needed by families in order to cope with 
each stage of the illness; initial encounter, 
first treatment provision, discharge, relapse 
and rehabilitation and that there is a lack of 
formal supports currently available. 
The study reveals that people who have a 
family member with an enduring mental 
Information Systems and in-house 
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illness feel socially isolated.  Families want 
to promote the fact that people with a 
mental illness do get well, and can recover 
their functioning in the community.
Recommendations emerging from the study 
focus on the need for:
improved public understanding of  
mental illness – this would help 
integration back into the community  
and reduce social isolation 
family support at the onset of mental 
health problems and at various stages 
throughout the care process 
an approachable mental health services 
contact, a key co-worker or ‘mediator’, 
between families, service users and 
mental health service providers, to help 
create a continuity of care through each 
stage of the mental illness 
tailored support services for the family 
members. 
Blood borne viruses among  
injecting drug users in Ireland 
A new HRB report shows that the number 
of injecting drug users with HIV, hepatitis B 
or hepatitis C is higher now than in the early 
1990s. Almost 70% of injecting drug users 
tested positive for antibodies to hepatitis 
C, and 20% tested positive for hepatitis B. 
Almost 10% of injecting drug users are HIV-
positive. 
It is well known that injectors have a higher 
risk of overdosing or acquiring blood-borne 
diseases such as hepatitis C, hepatitis B 
and HIV. This highlights the importance of 
providing harm reduction facilities for those 
who continue to inject.
The HRB Overview report makes the 
following recommendations for future 
research and action:
Quantify the success and effectiveness 
of current services, specifically needle 
exchange, opiate detoxification and 
opiate maintenance programmes, in 







Record risk factors associated with newly 
diagnosed cases of hepatitis C. 
Create a register to quantify the incidence 
and prevalence of hepatitis C among all 
heroin and cocaine users, and facilitate 
assessment of the main risk factors, 
treatment uptake and outcomes. 
Adopt strategies to increase the uptake of 
and compliance with HIV and hepatitis 
C therapy in prisons and in community 
settings. 
Estimate the medical consequences of, 
and interventions required to deal with, 
hepatitis C among injecting drug users. 
Develop a system to monitor the uptake 
of hepatitis B vaccine among prisoners, 
injecting drug users and sex workers. 
The relationship between drugs 
and crime
The starting point for strategies that aim 
to reduce drug-related crime in Ireland 
must be a genuine understanding of the 
complicated relationship between drugs 
and crime, according to a new report we 
published in May. The report aims to inform 
the development of effective policy responses 
which could contribute to the reduction of 
drug-related crime. It analyses the evidence 
available about drugs and crime in Ireland 
and suggests areas for further investigation:
Factors which encourage some drug users 
into further use and offending behaviour.
The relationship between the use of 
specific drugs and drug-related crime. 
Research on: 
the impact of drug-related crime at 
the local level 
drug users who are not in the 
criminal justice system 
polydrug use and offending 
behaviour 
urban and rural differences 
alcohol and violent crime 
the relationship between illicit 

















drug use, crime and gender
the operation of illicit drug markets, 
from import level to local level.
Disability needs identified in 
two reports 
The report on intellectual disability reveals 
that, in spite of significant investment 
and record levels of service provision, the 
demand for full-time residential services is at 
its highest since 2001. This can be attributed 
largely to the baby boom in the 60s and 70s 
and the fact that people with an intellectual 
disability are now living longer. According 
to the report, which is based on the HRB 
intellectual disability database, if demand 
continues at the present rate and additional 
services are not provided in response, only 
a proportion of existing and emerging need 
can be met.
The report shows that in 2006 there were 
25,518 people registered on the National 
Intellectual Disability Database. Almost 
three in every five (14,668) have a severe 
intellectual disability. There are more males 
(57%) than females (43%) registered. 
The report highlights a clear relationship 
between level of disability, age, and type of 
service available; those who are younger 
and in the less severe range of intellectual 
disability tend to be in day care rather than 
in residential care. 
Ninety per cent of people registered on the 
national physical and sensory disability 
database (NPSDD) were receiving services 
in June 2005. A report on these services 
published in 2006 shows that, despite high 
levels of service provision, a large number 
of people are still awaiting assessment for 
a variety of services, and  a large number 
who have been assessed for services are still 
awaiting provision of those services.
The NPSDD report is based on information 
from 22,429 registrations. There are more 
males (52.5%) than females (47.5%) 
registered. Approximately two-thirds of 
all registrations are adults and one-third 
are children (under 18 years at time of 
■
■
reporting). The majority of people (79.0%) 
registered reported a physical disability; 
6.7% reported hearing loss/deafness, 5.6% 
reported a visual disability, 1.4% reported a 
speech and language disability and just over 
7% reported a combination of disabilities. 
Measuring Activity and  
Participation (MAP)
In 2006, the Disability Databases Unit 
produced its first bulletin based on 
Measuring Activity and Participation (MAP) 
data recorded on the database. The MAP 
element of the NPSDD form, introduced in 
2004, has sections relating to:
barriers and challenges 
participation in everyday activities, and 
the World Health Organization Disability 
Assessment Schedule (WHODAS II).
This additional data captures a more 
holistic picture of the experience and service 
needs of the person with a disability.  MAP 
Bulletin No. 1 provides an overview of 
the kind of information that is collected 
as well as a profile of the people who have 
completed this section of the data form.  
Few countries possess data collection tools 
that capture information in the range and 
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The Corporate Function team provides 
specialist skills that help support the 
effective delivery of HRB services. 
Working in conjunction with the rest of 
the organisation, the team helps to identify 
new areas of opportunity and introduce 
processes that will improve the quality of 
service we provide to our customers. Some 
key organisation-wide activities in 2006 are 
described below.
Corporate Strategy
The HRB engaged in major consultation 
with stakeholders throughout 2006 in the 
process of drafting the Corporate Strategy 
2007–2011. The Strategy was prepared 
following rigorous analysis of the many 
changes taking place in the environment 
in which the HRB operates, taking into 
account the opportunities that now present 
for health research in Ireland. It reflects two 
major changes that have taken place in the 
past five years: specifically, health research 
is now at the heart of government policy on 
science, technology and innovation, and the 
HRB has a much greater capacity to support 
health research. 
The Strategy outlines six core objectives for 
the next five years:
To shape the national agenda for research 
in health and personal social services.
To support research and health 
information systems linked to national 
health priorities.





To advance the contribution that 
health research makes to a sustainable 
knowledge economy.
To increase awareness and understanding 
of both the impact and value of health 
information and research.
To establish Ireland as a significant 
contributor to international policy on 
health research.
We will realise the objectives of this strategy 
by working closely with our partners in 
the health service, universities, institutions 
and charities.  We believe that the results 
of our strategy will be seen in a healthier 
population, a much better health system and 
an enhanced contribution by health research 
to the knowledge economy in Ireland. 
Restructuring
The HRB has established a new structure 
to reflect the services we provide. There are 
three new directorates:
Corporate Function oversees the effective 
and efficient delivery of our support 
services: finance, legal and governance, 
IT, HR, communications, and facilities. 
Health Information and in-house  
Research brings together all our national 
information systems and research. 
There are four specialist units in this 
directorate: mental health research, 
alcohol and drug research, disability 
databases and child health epidemiology.
Research Strategy and Funding unites all 









This new directorate comprises three 
units:
The Research Management Unit 
will manage all funding for projects, 
programmes, career development and 
training.
The Research Infrastructure and 
Special Initiatives Unit will focus 
on major infrastructure investments 
such as research centres, facilities and 
networks.
The Policy, Evaluation and External 
Relations Unit will assess the 
outcomes and impact of HRB-funded 
research, develop policy relevant 
to funding and build relations with 
external funding agencies.
We hope that this new arrangement will 
make it easier for our stakeholders to engage 
with the HRB, whether as grant applicants, 
HRB-funded researchers, independent 
researchers, service planners or interested 
members of the public. 
HRB Conference: Today’s 
health research is tomorrow’s 
health care
The HRB hosted a major all-island 
conference in 2006. The aim of our 
conference was to inform the future 
shape and development of health research 
and policy in Ireland. More than 250 
participants from a variety of health and 
academic disciplines heard, and responded 
to, speakers who outlined the value of health 




better patient care 
more effective health policy and services 
a stronger knowledge economy and 
society. 
The conference was an essential forum 
which brought together people involved 
in research, health care, industry and 
service provision. This dynamic gave rise 
to animated discussion and exchange of 
ideas about the future of health research 
nationally, captured in a consensus 
statement after the conference.
Health and safety 
During 2006 the HRB employed Nifast 
to conduct a review of the HRB safety 
statement and complete a full risk 
assessment on both our office buildings. 
These risk assessments are detailed in the 
safety statement, and many tasks relating to 
them were addressed during the year. The 
amended safety statement will be circulated 
to all staff to sign in 2007. 
We are pleased that no health and safety 
incidents were reported during the course of 
the year.
Freedom of Information
The HRB came under FOI legislation in 
May 2006.  The HRB aims to provide as 
much information as possible so that people 
do not need to make applications under the 
Act. Details of how to request information 
are given on the HRB website at www.hrb.
ie. They are also available in our FOI Section 
15 and 16 Manual, which can be collected 





























This year, the HRB reinforced its long-term 
collaboration with the Wellcome Trust when 
the two organisations teamed up to support 
a proposal for a Clinical Research Facility 
in Dublin. The facility will provide the 
infrastructure – the physical space, facilities 
and the experts – needed to support patient-
focused research studies within a hospital 
setting and will ultimately improve the 
health of patients. 
The total investment will be in the order of 
€20 million over the next five years. The 
investment is a major boost for clinical 
research and patient care in Ireland, and it 
will provide a world-class environment for 
patient-focused research with real benefits 
for health. 
The HRB/Wellcome Trust CRF will be 
built on the grounds of St James’s Hospital. 
The successful proposal came from three 
Dublin medical schools at Trinity College, 
University College Dublin and the Royal 
College of Surgeons in Ireland and their 
affiliated teaching hospitals. The competitive 
proposal was led by Professor Dermot 
Kelleher, based at Trinity College/St James’s 
Hospital and was co-ordinated through the 
Dublin Molecular Medicine Centre. 
Cochrane Collaboration 
The HRB continued to support excellent 
opportunities for Irish researchers through 
Cochrane training and research fellowships. 
We were also lead sponsors of the Cochrane 
Colloquium, which met in Ireland for 
the first time in 2006. More than 800 
health practitioners, patients, information 
specialists, carers and policy makers from 40 
countries converged on Dublin to discuss the 
importance and impact of research evidence 
in relation to making everyday decisions 
about health. The event was also beamed 
to thousands more people via the internet. 
Fáilte Ireland estimated that the event was 
worth more than €1 million to the Irish 
economy.
All-Ireland/US Cancer  
Consortium 
In late 2006, the Irish, Northern Irish 
and American governments renewed 
their commitment to the historic Ireland–
Northern Ireland–NCI Cancer Consortium 
by signing a second Memorandum of 
Understanding. 
The goal of the Consortium is to reduce 
the incidence and mortality of cancer on 
the island of Ireland by enhancing the 
infrastructure for cancer research and cancer 
care. Since 1999 the HRB has strongly 
supported the work of the Consortium. 
Working in partnership – a look at 
some collaborative work 
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Outcomes to date include:
200 people have graduated from the NCI 
summer curriculum in cancer prevention 
and control.
Four fellowships have been awarded to 
Irish people in areas of cancer prevention. 
Two joint research fellowships are under way.
Successful knowledge-sharing workshops 
were organised to address issues such as 
smoking cessation, cancer and obesity.
Irish Aid 
Millions of people living in poverty in 
developing countries die or suffer ill-health 
every year from largely preventable or 
treatable causes. Investment in research 
on the health problems of developing 
countries is essential to achieve better health 
outcomes and an improved quality of life. 
The HRB and Irish Aid recently signed a 
Memorandum of Understanding to work 
collaboratively to support global health 
research and to increase research capacity 
in developing countries. In 2006, the HRB 
launched a successful research funding 
call and six projects were selected through 
our peer-review process. Each of these 
projects will generate high-quality research 
evidence directly related to the policy areas 
of the Irish aid programme and will build 
research capacity in developing countries. 
It is hoped that the scheme will help to 
promote international partnerships in global 
health research, with special emphasis 
on collaborative projects involving Irish 
research institutions.
Medical Research Charities 
Group (MRCG)
The MRCG secured its first-ever 
Government funding of €1 million to 
supplement research by Irish health charities 
during the year. The HRB organised a 
workshop in conjunction with the MRCG 
in advance of the call for applications. This 
meeting gave the HRB the opportunity to 
share our experience of the peer-review 
process in assessing research applications, 
and of applying best international practice 





process. More than 40 applications were 
received from the medical research charities, 
and 33 projects were funded in 2006, which 
focus on a wide variety of common and rare 
diseases, from cancer to retinal pigmentosa 
and from epidermolysis bullosa to muscular 
dystrophy.
European Monitoring Centre 
for Drugs and Drug Addiction 
(EMCDDA)
The Alcohol and Drug Research Unit is 
the designated Irish focal point for the 
EMCDDA and provides objective, reliable 
and comparable information on drugs and 
drug addiction from the Irish perspective. 
Researchers compile an annual report 
containing new information on the situation, 
consequences and responses to drug use 
in Ireland. This information is collected in 
a standardised way by all European focal 
points, which allows valid comparisons 
between European countries on current 
patterns and emerging trends in drug use. 
Areas researched in detail in 2006 were drug 
use and related problems among children 
under 15 years old, the situation and 
responses with respect to cocaine, and the 
link between drug consumption and driving. 
National Advisory Committee 
on Drugs (NACD)
The Alcohol and Drug Research Unit 
works with the NACD to provide advice 
to the Government on problem drug use in 
Ireland in terms of prevalence, prevention 
consequences and treatment. During 2006, 
the unit assisted the NACD to commission 
the second national drug prevalence 
survey. This is a major undertaking as drug 
prevalence surveys of the general population 
shed light on the patterns of drug use, both 
demographically and geographically and, 
if repeated, can track changes over time. 
The results of this survey, which will be 
available in mid-2007, will help to increase 
our understanding of drug use, to formulate 
and evaluate drug policies and to enable 
informed comparisons with similar surveys 
internationally.
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Mental Health Commission 
The HRB worked closely with the Mental 
Health Commission during the year on the 
first comprehensive study of community 
residential mental health services in Ireland. 
The number of people living in community 
residences has risen from 900 to 3,065 in the 
past twenty years. These residences are now 
central to the provision of mental health 
services in Ireland and are shaping the lives 
of more than 3,000 people. This study will 
review the extent to which they are meeting 
the needs of service users. The results of the 
research, conducted by the HRB, will be 
published in early 2007.
National Institutes of Health 
(US) and Trinity College Dublin
The Child Health Epidemiology Unit 
continued its research into congenital 
malformations and other adverse pregnancy 
outcomes in conjunction with the National 
Institutes of Health and Trinity College 
Dublin and produced two peer-reviewed 
publications. The research team welcomed 
the Irish Government’s decision in 2006 to 
make mandatory the fortification of bread 
with folic acid to reduce the incidence of 
neural tube defects in children. This decision 
was influenced by the team’s research finding 
that folic acid in the diet has a marked 
protective effect against neural tube defects 
in pregnancy. 
Interim Health Information and 
Quality Authority (iHIQA) 
The HRB engaged with the Chief Executive 
of iHIQA, Dr Tracey Cooper, to brief her 
on the information systems managed by 
the HRB and the challenges facing all those 
involved in health information systems in 
the absence of national standards, unique 
patient/client identifiers and interoperability 
of systems. The HRB also assisted iHIQA to 
commission research relevant to its mission 
to improve the quality of health services and 
health information and to develop capacity 
in health technology assessment. 
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Department of Health and Children Revenue Grant 0,,000 27,147,000 
Other Research Funding ,0,1 1,209,572 
Interest Receivable 1,1 44,376 
Other Income 61,022 - 
Rental Income 2, 53,775 
 
 ,0, 28,454,723 
 
Expenditure 
Research Funding and Policy Division 21,0,26 16,562,617 
Child Health Epidemiology Division 10,6 692,823 
Drug Misuse Research Division 1,216,6 1,071,773 
Mental Health Research Division 6,61 666,667 
Disability Databases Division 2, 426,716 
R&D for Health Division 11,1,1 4,499,941 
Administration Costs and General Overheads 2,62,0 2,351,018 
Pensions Paid to Retired Members of Staff , (10,849)
 
 ,6,0 26,260,706 
 
(DEFICIT)/SURPLUS FOR THE YEAR (,2,20) 2,194,017 
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REVENUE RESERVES AT 1 DECEMBER 2,6 4,330,416
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Appendix 1:  
Organisational review 
International Panel Members
The HRB Organisational review took place in November 2005. The report from the panel was 
presented in January 2006.
The panel members included:
Dr Don Thornhill, Chair, National Competitiveness Council (Chair of the Panel)
Professor Alun Evans, Department of Epidemiology and Public Health, Queen’s University, 
Belfast 
Dr Paulette Gray, Director, Division of Extramural Activities, National Cancer Institute, USA 
Mr John O’Brien, CEO, St James’s Hospital, Dublin 
Mr Gerry O’Hanlon, Director, Social and Demographic Statistics, Central Statistics Office, 
Dublin 
Professor Alan Pettigrew, Chief Executive, National Health and Medical Research Council of 
Australia 
Mr Lewis Purser, Assistant Director, Irish Universities Association, Dublin 
Professor John Williams, Director, Wales Office of Research and  
Development in Health and Social Care
Dr Mary-Patricia McKeever, rapporteur
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